Palisades Investment Partners LLC Has $9.98 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Palisades Investment Partners LLC lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 7.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 160,108 shares of the company's stock after buying an additional 11,323 shares during the period. TransMedics Group accounts for approximately 4.2% of Palisades Investment Partners LLC's holdings, making the stock its 7th biggest position. Palisades Investment Partners LLC owned 0.48% of TransMedics Group worth $9,983,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of TMDX. Arizona State Retirement System grew its position in TransMedics Group by 1.9% in the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after purchasing an additional 184 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock worth $294,000 after purchasing an additional 317 shares during the last quarter. Park Avenue Securities LLC grew its position in TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock worth $548,000 after purchasing an additional 322 shares during the last quarter. Atlas Capital Advisors Inc. bought a new position in TransMedics Group in the 4th quarter worth about $31,000. Finally, Alliancebernstein L.P. grew its position in TransMedics Group by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after purchasing an additional 500 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 2.7%

TMDX stock opened at $121.31 on Thursday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The firm has a market cap of $4.10 billion, a PE ratio of 129.05 and a beta of 1.91. The firm has a 50 day simple moving average of $87.35 and a 200 day simple moving average of $76.74. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $143.54 million during the quarter, compared to analyst estimates of $123.39 million. During the same period in the prior year, the business earned $0.35 earnings per share. The business's quarterly revenue was up 48.2% on a year-over-year basis. Equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Piper Sandler restated an "overweight" rating and issued a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a research report on Friday, May 9th. Oppenheimer increased their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $126.70.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.